CAR-T cell therapy has revolutionised cancer treatment, offering life-changing outcomes for patients with haematological malignancies. Jean-Pierre Latere, PhD, CEO of EsoBiotec, discusses advances in in vivo engineering, which are poised to overcome manufacturing and cost barriers, making these therapies more accessible and expanding their potential applications. The landscape of cancer treatment has been fundamentally transformed […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!